|52Wk High:||52Wk Low:|
MYOS Corp. is an emerging bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of MYO-T12, also known as Fortetropin, the first clinically demonstrated natural myostatin inhibitor. Myostatin is a natural regulatory protein that inhibits muscle growth and recovery. Fortetropin is manufactured to optimize biological activity and has the potential to redefine existing standards for muscle health.